¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"angiotensin receptor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® receptor ÇÑ±Û ¼ö¿ëü
¼³¸í   
  ¼¼Æ÷Áú³» ¶Ç´Â ¼¼Æ÷Ç¥¸é¿¡ Á¸ÀçÇϴ ºÐÀÚ±¸Á¶·Î¼­ Æ¯À̹°Áú°ú ¼±ÅÃÀûÀ¸·Î °áÇÕÇϸ砰áÇÕ¿¡ ÀÇÇØ Æ¯ÀÌÇÑ »ý¸®Àû ÀÛ¿ëÀ» ³ªÅ¸³½´Ù. ÆéƼµåÈ£¸£¸ó, ½Å°æÀü´Þ¹°Áú, Ç׿ø, º¸Ã¼, ¸é¿ª±Û·ÎºÒ¸°¿¡ ´ëÇÑ ¼¼Æ÷Ç¥¸é ¼ö¿ëü¿Í ½ºÅ×·ÎÀ̵忡 ´ëÇÑ ¼¼Æ÷Áú³» ¼ö¿ëü°¡ ÀÖ´Ù.
¿µ¹® angiotensin ÇÑ±Û ¾ÈÁö¿ÀÅÙ½Å
¼³¸í   
  ÄáÆÏ¿¡¼­ ½ÅÀåÀÇ Ç÷·ù¿Í Ç÷¾ÐÀ» °¨ÁöÇϴ ¼¼Æ÷ÀΠġ¹Ð¹ÝÁ¡(macula densa)°ú Å丮°ç¼¼Æ÷(JG cell)¿¡¼­ Ç÷·ù¿Í Ç÷¾ÐÀÇ ÀúÇϰ¡ ÀÖÀ» °æ¿ì¿¡ ·¹´ÑÀ̶ó´Â ¹°ÁúÀÌ ºÐºñµÇ°Ô µÈ´Ù. ÀÌ ·¹´ÑÀ̶ó´Â ¹°ÁúÀº Ç÷Áß¿¡ Á¸ÀçÇϴ ¾ÈÁö¿ÀÅÙ½ÅÀ̶ó´Â ¹°ÁúÀ» ¾ÈÁö¿ÀÅٽŠIÀ¸·Î º¯È­½Ã۰í ÀÌ ¾ÈÁö¿ÀÅٽŠIÀ̶ó´Â ¹°ÁúÀº ¾ÈÁö¿ÀÅٽŠI Àüȯȿ¼Ò¿¡ ÀÇÇØ¼­ ¾ÈÁö¿ÀÅÙ½ÅII¶ó´Â ¹°Áú·Î µÈ´Ù. ¾ÈÁö¿ÀÅٽŰú ¾ÈÁö¿ÀÅٽŠIÀ̶ó´Â ¹°ÁúÀº ±× ÀÛ¿ëÀÌ °ÅÀÇ ¾øÁö¸¸ ¾ÈÁö¿ÀÅٽŠII¶ó´Â ¹°ÁúÀº °­·ÂÇϰԠÇ÷°ü¼öÃàÀ» ½Ã۰í À̷ΠÀÎÇØ¼­ Ç÷¾ÐÀÇ »ó½ÂÀ» °¡Á®¿À¸ç µ¿½Ã¿¡ ºÎ½ÅÀ» ÀÚ±ØÇÏ¿© ¾Ëµµ½ºÅ×·ÐÀ» ºÐºñÇϰԠÇÑ´Ù. ¾ÈÁö¿ÀÅÙ½ÅÀ̶õ Ç÷°üÀ» ¼öÃà½ÃŰ°í ¾Ëµµ½ºÅ×·ÐÀÇ ºÐºñ¸¦ À¯µµÇÔÀ¸·Î½á Ç÷¾ÐÀÇ »ó½ÂÀ» °¡Á®¿À´Â ¹°ÁúÀÌ´Ù. ±×¸®°í ±× ÀÛ¿ëÀº ·¹´Ñ-¾ÈÁö¿ÀÅÙ½Å-¾Ëµµ½ºÅ×·ÐÀ¸·Î À̾îÁö´Â Ã¼°è¿¡ ÀÇÇØ¼­ Á¶ÀýµÇ°í ÀÌ·ç¾îÁø´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • angiotensin
    ¾ØÁö¿ÀÅÙ½Å
  • angiotensin converting enzyme
    ¾ØÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò
  • angiotensin converting enzyme inhibitor
    ¾ØÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò¾ïÁ¦Á¦
  • renin-angiotensin-aldosterone system
    ·¹´Ñ-¾ØÁö¿ÀÅÙ½Å-¾Ëµµ½ºÅ׷аèÅë
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • adrenergic receptor
    ¾Æµå·¹³¯¸°¼ö¿ëü
  • androgen receptor
    ¾Èµå·Î°Õ¼ö¿ëü
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼ö¿ëüÀλêÈ­È¿¼Ò
  • cold receptor
    ³Ã°¢¼ö¿ë±â
  • complement receptor
    º¸Ã¼¼ö¿ëü
  • corpuscular receptor
    ¼Òü¼ö¿ëü
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cholinergic receptor
    Äݸ°¼ö¿ëü
  • distance receptor
    ¿ø°Ý¼ö¿ë±â
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • angiotensin
    ¾ÈÁö¿ÀÅÙ½Å
  • angiotensin converting enzyme
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò
  • receptor blocker
    ¼ö¿ëüÂ÷´ÜÁ¦
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • receptor
    ¼ö¿ëü, ¼ö¿ë±â
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • opiate receptor
    ¾ÆÆí¼ö¿ëü
  • sensory receptor
    °¨°¢¼ö¿ëü
  • receptor site
    ¼ö¿ëüºÎÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • angiotensin
    ¾ÈÁö¿ÀÅÙ½Å
  • angiotensin converting enzyme
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò
  • adrenergic receptor
    ¾Æµå·¹³¯¸°¼ö¿ëü
  • androgen receptor
    ¾Èµå·Î°Õ¼ö¿ëü
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • receptor autoradiography
    ¼ö¿ëüÀÚ°¡¹æ»ç¼±¼ú
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼º¼ö¿ëüÀλêÈ­È¿¼Ò
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • receptor blocker
    ¼ö¿ëüÂ÷´ÜÁ¦
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cholinergic receptor
    Äݸ°¼ö¿ëü
  • cold receptor
    ³Ã°¢¼ö¿ëü
  • complement receptor
    µµ¿òü¼ö¿ëü, º¸Ã¼¼ö¿ëü
  • corpuscular receptor
    ¼Òü¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ACE : angiotensin converting enzyme
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò.
  • ACE=> angiotensin converting enzyme
    ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò(ï®üµý£áÈ)
  • ACEI : angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò¾ïÁ¦Á¦(ï®ü½ý£áÈåäð¤ð¥).
  • angiotensin
    ¾ÈÁö¿ÀÅÙ½Å
  • angiotensin converting enzyme
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò.
  • angiotensin converting enzyme inbibitor
    ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò ¾ïÁ¦¹°Áú<¾à>.
  • angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò ¾ïÁ¦¹°Áú<¾à>.
  • angiotensin ii
    ¾ÈÁö¿ÀÅÙ½ÅII
  • angiotensin-converting enzyme
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò
  • renin angiotensin aldosterone pressor
    ·¹´Ñ¾ÈÁö¿ÀÅٽž˵µ½ºÅ׷н ¾Ð°è(¡­ã°äâ
  • renin angiotensin system
    ·¹´Ñ¾ÈÁö¿ÀÅٽŰè(¡­Í§).
  • renin-angiotensin system
    ·¹´Ñ¾ÈÁö¿ÀÅÙ½Åü°è
  • renin-angiotensin system
    ·¹´Ñ-¾ÈÁö¿ÀÅٽŰè(¡­Ìõ)
  • renin-angiotensin-aldosterone axis
    ·¹´Ñ-¾ÈÁö¿ÀÅÙ½Å-¾Ëµµ½ºÅ×·ÐÃà<--°è>
  • renin-angiotensin-aldosterone system
    ·¹´Ñ-¾ÈÁö¿ÀÅÙ½Å-¾Ëµµ½ºÅ×·Ðü°è
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • angiotensin
    ¾ÈÁö¿ÀÅÙ½Å
  • angiotensin converting enzyme
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò.
  • angiotensin converting enzyme inbibitor
    ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò ¾ïÁ¦¹°Áú<¾à>.
  • angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò ¾ïÁ¦¹°Áú<¾à>.
  • angiotensin ii
    ¾ÈÁö¿ÀÅÙ½ÅII
  • angiotensin-converting enzyme
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò
  • renin angiotensin aldosterone pressor
    ·¹´Ñ¾ÈÁö¿ÀÅٽž˵µ½ºÅ׷н ¾Ð°è(¡­ã°äâ
  • renin angiotensin system
    ·¹´Ñ¾ÈÁö¿ÀÅٽŰè(¡­Í§).
  • renin-angiotensin system
    ·¹´Ñ¾ÈÁö¿ÀÅÙ½Åü°è
  • renin-angiotensin system
    ·¹´Ñ-¾ÈÁö¿ÀÅٽŰè(¡­Ìõ)
  • renin-angiotensin-aldosterone axis
    ·¹´Ñ-¾ÈÁö¿ÀÅÙ½Å-¾Ëµµ½ºÅ×·ÐÃà<--°è>
  • renin-angiotensin-aldosterone system
    ·¹´Ñ-¾ÈÁö¿ÀÅÙ½Å-¾Ëµµ½ºÅ×·Ðü°è
  • acetylcholine receptor
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü
  • acetylcholine receptor
    ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • acetylcholine receptor antibody
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëüÇ×ü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Receptor
    ¼ö¿ë±â
    [¿¾ ¿ë¾î] ¼ö¿ë±â
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • angiotensin I
    ¾ÈÁö¿ÀÅٽŠI
  • angiotensin II
    ¾ÈÁö¿ÀÅٽŠII
  • adrenergic receptor
    ¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) ¼ö¿ëü(áôé»ô÷)
  • alpha adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³ª¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷)
  • alpha receptor
    ¾ËÆÄ¼ö¿ëü(áôé»ô÷)
  • beta adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸° ¼ö¿ëü(áôé»ô÷)
  • beta receptor
    º£Å¸ ¼ö¿ëü(áôé»ô÷)
  • cyclic AMP receptor protein
    °í¸®AMP ¼ö¿ëü ´Ü¹éÁú(áôé»ô÷Ó±ÛÜòõ)
  • dopamine adrenergic receptor
    "µµÆÄ¹Î ¾Æµå·¹³¯¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷), (ÔÒ) adrenergic receptor"
  • Ehrlich's receptor theory
    ¿¡¸¦¸®È÷ ¼ö¿ëüÀÌ·Ð(áôé»ô÷×âÖå)
  • Fc receptor
    Fc ¼ö¿ëü(áôé»ô÷)
  • floating receptor model
    ºÎÀ¯ ¼ö¿ëü(Ý©ë´áôé»ô÷) ¸ðµ¨
  • glucocorticoid receptor
    ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀÌµå ¼ö¿ëü(áôé»ô÷)
  • H1 receptor
    H1 ¼ö¿ëü(áôé»ô÷)
  • H2 receptor
    H2 ¼ö¿ëü(áôé»ô÷)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • angiotensin
    ¾ÈÁö¿ÀÅÙ½Å
  • receptor
    ¼ö¿ë±â, ¼ö¿ëü, °¨¼öü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ER efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re...
RAR rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ...
ACE Angiotensin Converting Enzyme
  = Kininase II
  = Dipeptidyl Carboxypepti...
RAA Renin-Angiotensin-Aldosterone
AI, AII, AIII angiotensin I, II, III
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AT1-R Angiotensin II type 1 receptor
ARB angiotensin receptor blocker
ARB Angiotensin II receptor blocker
AT1 Angiotensin II receptor type 1
AT1 Angiotensin type 1 receptor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • angiotensin
    ¾ÈÁö¿ÀÅÙ½Å
    1. °­·ÂÇÑ Ç÷°ü ¼öÃà ÀÛ¿ë°ú ºÎ½Å ÇÇÁú¿¡¼­ÀÇ ¾Ëµµ½ºÅ×·Ð »ýÇÕ¼º ¹× ºÐºñ ÃËÁøÀÛ¿ëÀÌ ÀÖ´Ù. ºÐÀÚ·®À» ±âÁØÀ¸·Î ³ë¿¡Çdz×ÇÁ¸°¿¡ ºñÇØ ¾à 40¹è³ª °­ÇÑ Ç÷¾Ð »ó½Â È¿°ú¸¦ °¡Áö°í ÀÖ´Ù. 2. Ç÷¾×¿¡ Á¸ÀçÇÏ´Â Æú¸® ÆéŸÀ̵å·Î¼­ Ç÷ÀåÀÇ ·¹´Ñ°ú Ç÷û a2 ±Û·ÎºÒ¸°¿¡ ÀÇÇÏ¿© Çü¼ºµÈ´Ù. deca
  • angiotensin converting enzyme
    ¾ÈÁö¿ÀÅٽŠÀüȯ È¿¼Ò
  • angiotensin I
    ¾ÈÁö¿ÀÅٽŠI
    ºÒȰ¼ºÇüÀ¸·Î ÆéŸÀÌµå ºÐÇØ È¿¼ÒÀÇ ÀÛ¿ë¿¡ ÀÇÇÏ¿© ¿ÁŸÆéŸÀ̵åÀÇ ¾ÈÁö¿ÀÅٽŠ¥±·Î ÀüȯµÈ´Ù. À̰ÍÀÌ °­·ÂÇÑ Ç÷°ü ¼öÃà ¹°ÁúÀÌ¸ç ¶ÇÇÑ ºÎ½Å ÇÇÁú¿¡¼­ ¾Ëµµ½ºÅ×·Ð ºÐºñ ÃËÁø ¹°ÁúÀ̱⵵ ÇÏ´Ù.
  • angiotensin-converting enzyme
    ¾ÈÁö¿ÀÅٽŠÀüȯ È¿¼Ò
  • 5-HT1 receptor antagonist
    5-HT1 ¼ö¿ë±â ±æÇ×Á¦
    ÀÏÂïÀÌ 5-hydroxytry
  • A1 receptor
    A1 ¼ö¿ëü, A1 ¼ö¿ë±â, A1 °¨¼ö±â
  • acetylcholine receptor
    ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸° ¼ö¿ëü
  • antigen receptor
    Ç׿ø ¼ö¿ëü
  • beta receptor blocker
    º£Å¸ ¼ö¿ëü Â÷´ÜÁ¦
  • C3 receptor
    C3 ¼ö¿ëü
    Ç÷¾× ¼ÓÀÇ ¿©·¯ ¼¼Æ÷¿¡´Â º¸Ã¼ Á¦ 3¼ººÐ¿¡ ´ëÇÑ ¼ö¿ëü¸¦ °¡Áö°í ÀÖ´Â °ÍÀÌ ÀÖ´Ù. B ¸²ÇÁ±¸´Â C3b ¹× C3dÀÇ ¼ö¿ëü¸¦ °¡Áö°í ÀÖ´Ù. T ¸²ÇÁ±¸´Â C3b ¼ö¿ëü´Â À̹ۿ¡ È£Áß±¸, macro
  • deep receptor
    ½ÉºÎ ¼ö¿ëü
  • distance receptor
    °Å¸® ¼ö¿ë±â
  • dominant receptor
    ¿ì¼º ¼ö¿ëü
  • dopamine receptor
    µµÆÄ¹Î ¼ö¿ëü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
angiotensin <hormone> A family of oligopeptides ranging in size from angiotensin precursors with 14 amino acids to the active vasoconstrictor angiotensin II with 8 amino acids, or their analogs or derivatives.
The amino acid content varies with the species and changes in that content produce antagonistic or inactive compounds.
Angiotensinogen (renin substrate) is a 60 kD polypeptide released from the liver and cleaved in the circulation by renin to form the biologically inactive decapeptide angiotensin I. This is in turn cleaved to form active angiotensin II by Angiotensin-converting Enzyme (ACE). Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases.
(12 Aug 2000)
angiotensin amide <chemical> 1-l-asparagine-5-l-valine-angiotensin II. The octapeptide amide of bovine angiotensin II used to increase blood pressure by vasoconstriction.
Pharmacological action: vasoconstrictor agents.
Chemical name: Angiotensin II, 1-L-asparagine-5-L-valine-
(12 Dec 1998)
angiotensin-converting enzyme <enzyme> This hydrolase enzyme cleaves the decapeptide angiotensin I (biologically inactive) to form active angiotensin II by angiotensin-converting enzyme which removes a dipeptide (histidylleucine) from angiotensin I.
Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases.
Elevations in angiotensin converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels).
Drugs that inhibit ACE are used to treat hypertension and congestive heart failure.
See: angiotensin-converting enzyme inhibitor
Acronym: ACE
(12 Aug 2000)
angiotensin-converting enzyme inhibitor <pharmacology> A class of drugs used in the treatment of hypertension and heart failure.
They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
(14 Aug 2000)
angiotensin-converting enzyme secretase <enzyme> Converts ace from a membrane-bound to a soluble form; not inhibited by thiol, serine or acid enzyme inhibitor but is inhibited by edta and 1,10-phenanthroline
Registry number: EC 3.4.99.-
Synonym: ace secretase
(26 Jun 1999)
angiotensin I <chemical> The decapeptide precursor of angiotensin II, generated by the action of renin on angiotensinogen. It has limited pharmacologic activity.
Chemical name: Angiotensin I
(12 Dec 1998)
angiotensin II <chemical> The active form of angiotensin. An octapeptide found in blood, it is synthesised from angiotensin I and quickly destroyed. Angiotensin II causes profound vasoconstriction with resulting increase in blood pressure. The clinically and experimentally used bovine form has valine in position 5 where the human form has isoleucine.
Pharmacological action: vasoconstrictor agents.
Chemical name: Angiotensin II
(12 Dec 1998)
angiotensin III <chemical> A heptapeptide formed by the enzymatic hydrolysis of angiotensin II. It has greater activity than angiotensin II for stimulating aldosterone synthesis and in the release of prostaglandins but only 20% of the pressor activity.
Chemical name: Angiotensin II, 1-de-L-aspartic acid-
(12 Dec 1998)
angiotensin I (Phe 8-His 9) hydrolase <enzyme> Cleaves the cooh-terminal dipeptide his(9)-leu(10) from the decapeptide angiotensin i
Registry number: EC 3.4.15.-
Synonym: atypical angiotensin-converting enzyme
(26 Jun 1999)
angiotensin precursor angiotensin
angiotensin-related carboxypeptidase <enzyme> Rat and bovine brain synaptosomal enzyme can hydrolyze angiotensin I to des-leu angiotensin I, but no further
Registry number: EC 3.4.-
Synonym: angiotensin-specific carboxypeptidase
(26 Jun 1999)
receptors, angiotensin Cell surface proteins that bind angiotensins and trigger intracellular changes influencing the behaviour of cells.
(12 Dec 1998)
renin-angiotensin-aldosterone system The hormones, renin, angiotensin, and aldosterone work together to regulate blood pressure. A sustained fall in blood pressure causes the kidney to release renin. This is converted to angiotensin in the circulation. Angiotensin then raises blood pressure directly by arteriolar constriction and stimulates adrenal gland to produce aldosterone which promotes sodium and water retention by kidney, such that blood volume and blood pressure increase.
(05 Mar 2000)
renin-angiotensin system <physiology> A system consisting of renin, angiotensin-converting enzyme, and angiotensin II.
Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming angiotensin I. The converting enzyme contained in the lung acts on angiotensin I in the plasma converting it to angiotensin II, the most powerful directly pressor substance known. It causes contraction of the arteriolar smooth muscle and has other indirect actions mediated through the adrenal cortex.
(25 Jun 1999)
1-sarcosine-8-isoleucine angiotensin II <chemical> An angiotensin II analog which acts as a highly specific inhibitor of angiotensin II.
Pharmacological action: angiotensin-converting enzyme inhibitors, antihypertensive agents.
Chemical name: Angiotensin II, 1-(N-methylglycine)-8-L-isoleucine-
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • angiotensin
    ¾ØÁö¿ÀÅÙ½Å(Ç÷¾× Áß¿¡ ¸¸µé¾îÁö´Â Ç÷¾Ð »ó½Â ¹°Áú)
  • receptor
    ¼ö¿ë±â;°¨°¢±â°ü;¼ö¿ëü
  • receptor site
    ¼¼Æ÷³» ¼ö¿ë ¿µ¿ª
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á